• the increasing focus by companies in China to vertically integrate and consolidate their supply chains fully with products manufactured in China; 

• our ability to develop, introduce, manufacture and ship new and enhanced products in a timely manner without defects; 

• our ability to manage our manufacturing capacity across our diverse product lines and that of our suppliers, including our ability to successfully expand our manufacturing capacity in various locations around the world; 

• our ability to successfully and fully integrate acquisitions, such as the historical Rofin businesses, into our operations and management; 

• our ability to successfully internally transfer the manufacturing of products and related operations as part of our integration and internal reorganization efforts and to realize anticipated benefits (including savings) therefrom, such as with our recently announced plan to co- locate the manufacturing and engineering of our High Power Fiber Lasers ("HPFL") products at our Hamburg, Germany, facility to our Tampere, Finland, location and exit a portion of our HPFL business, expected to be completed during fiscal 2020; 

• our reliance on contract manufacturing; 

• our reliance in part upon the ability of our OEM customers to develop and sell systems that incorporate our laser products; 

• our customers' ability to manage their susceptibility to adverse economic conditions; 

• the rate of market acceptance of our new products; 

• the ability of our customers to pay for our products; 

• expenses associated with acquisition-related activities, including the costs of acquiring businesses or technologies; 

• seasonal sales trends, including with respect to Rofin's historical business, which has traditionally experienced a reduction in sales during the first half of its fiscal year as compared to the second half of its fiscal year; 

• jurisdictional capital and currency controls negatively impacting our ability to move funds from or to an applicable jurisdiction; 

• access to applicable credit markets by us, our customers and their end customers; 

• the impact of rising Chinese consumer debt and eroding consumer confidence and spending in China; 

• delays or reductions in customer purchases of our products in anticipation of the introduction of new and enhanced products by us or our competitors; 

• our ability to control expenses; 

• the level of capital spending of our customers; 

• potential excess and/or obsolescence of our inventory; 

• costs and timing of adhering to current and developing governmental regulations and reviews relating to our products and business, including import and export regulations in multiple jurisdictions; 

• impairment of goodwill, intangible assets and other long-lived assets; 

• our ability to meet our expectations and forecasts and those of public market analysts and investors; 

• the availability of research funding by governments with regard to our customers in the scientific business, such as universities; 

